View of Post incorporation monitoring into the Brazilian Public Health System: an analysis of Infliximab, Vedolizumab and Tofacitinib for the treatment of ulcerative retocolitis | JORNAL DE ASSISTÊNCIA FARMACÊUTICA E FARMACOECONOMIA